Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan;145(1):211-214.e1.
doi: 10.1016/j.jid.2024.06.1272. Epub 2024 Jun 28.

Cutaneous T-Cell Lymphoma after Dupilumab Use: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System

Leore Lavin  1 , Stephen Dusza  1 , Shamir Geller  2
Affiliations

Cutaneous T-Cell Lymphoma after Dupilumab Use: A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System

Leore Lavin et al. J Invest Dermatol. 2025 Jan.
No abstract available

Keywords: Adverse event; Biologics; Cutaneous T-cell lymphoma; Dupilumab; Pharmacovigilance.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest Statement: The authors state no conflict of interest.

References

    1. Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Pinto PH, Pujol RM, Szepietowski JC, Ettler K, Kemény L, … Shumel B (2017). Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet, 389(10086), 2287–2303. 10.1016/s0140-6736(17)31191-1 - DOI - PubMed
    1. Boesjes CM, van der Gang LF, Bakker DS, ten Cate TA, Spekhorst LS, de Graaf M, van Dijk MR, & de Bruin-Weller MS (2023). Dupilumab-Associated Lymphoid Reactions in Patients With Atopic Dermatitis. JAMA Dermatology, 159(11), 1240–1247. 10.1001/jamadermatol.2023.3849 - DOI - PMC - PubMed
    1. Cohen JM, Damsky W, & Girardi M (2022). Comment on “Diagnostic testing of eczematous dermatitis with incomplete response to dupilumab”. Journal of the American Academy of Dermatology, 87(6), e241–e242. 10.1016/j.jaad.2022.05.069 - DOI - PubMed
    1. Geskin LJ, Viragova S, Stolz DB, & Fuschiotti P (2015). Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation. Blood, 125(18), 2798–2805. 10.1182/blood-2014-07-590398 - DOI - PMC - PubMed
    1. Hasan I, Parsons L, Duran S, & Zinn Z Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study. Journal of the American Academy of Dermatology. 10.1016/j.jaad.2024.03.039 - DOI - PubMed

LinkOut - more resources